---
schema_version: "secwatch.filing_event.v1"
accession: "0001013762-23-002136"
form_type: "8-K"
ticker: "ICCC"
cik: "0000811641"
company_name: "IMMUCELL CORP /DE/"
filed_at: "2023-10-05T23:59:59+00:00"
generated_at: "2026-06-10T04:22:34.358225+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# ImmuCell Q3 preliminary sales $5.4M (+13% YoY); backlog rises to $8.9M

## Summary
- Q3 2023 total sales $5.40M, up 13% from $4.80M in Q3 2022.
- Nine-month sales $12.38M, down 16% YoY; trailing twelve months $16.29M, down 19%.
- Finished goods production in Q3 was $5.3M, approximately 89% of the $6M quarterly goal.
- Order backlog increased to $8.9M from $8M at June 30, 2023 and $2.5M at Dec 31, 2022.
- Company overcame earlier contamination events; third FDA submission for Re-Tain under 6-month review.

## SEC filing metadata
- accession: 0001013762-23-002136
- form_type: 8-K
- ticker: ICCC
- cik: 0000811641
- company_name: IMMUCELL CORP /DE/
- filed_at: 2023-10-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/811641/000101376223002136/0001013762-23-002136-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/811641/000101376223002136/ea186386-8k_immucell.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001013762-23-002136
- JSON: https://secwatch.observer/filing/0001013762-23-002136.json
- Plain text: https://secwatch.observer/filing/0001013762-23-002136.txt

## Key facts
- Earnings Releases
  IMMUCELL CORP /DE/ reported quarter ended September 30, 2023 results: revenue $5.40 million.
  - Period: quarter ended September 30, 2023
  - Revenue: $5.40 million
  - Result: preliminary results
  source text: September 30, 2023. Preliminary, Unaudited Total Sales Results: 2023 2022 $ Increase ($ Decrease) % Increase (% Decrease) During the Three-Month Periods Ended September 30, $ 5.40 million $ 4.80 million $ 600,000 13 % During the Nine-Month Periods Ended September 30, $ 12.38 million $ 14.66 million $ (2.28 million ) (16 %) During the Trailing Twelve-Month Periods
  evidence_url: https://www.sec.gov/Archives/edgar/data/811641/000101376223002136/0001013762-23-002136-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.